PartnershipJul 14, 2026, 06:02 AM
Spero & Innovent Partner for SP001; Deal Valued at $1.1B
AI Summary
Spero Therapeutics and Innovent Biologics announced an exclusive license agreement for SP001 (IBI355), a third-generation Fc-silent anti-CD40L antibody. Under the terms, Spero gains exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001. Innovent will receive an upfront payment and is eligible for development, regulatory, and commercial milestone payments totaling approximately US$1.1 billion, plus tiered royalties on net sales. Spero plans to initiate a Phase 2 trial for SP001 in IgG4-related disease in Q2 2027, while Innovent plans a Phase 2 trial in China for Sjögren’s disease by early 2027.
Key Highlights
- Spero receives exclusive global rights (ex-Greater China) for SP001.
- Innovent eligible for up to $1.1 billion in development, regulatory, and commercial milestone payments.
- Innovent to receive tiered royalties on net sales in Spero's licensed territories.
- Spero plans to initiate a Phase 2 trial for SP001 in IgG4-RD in Q2 2027.
- Innovent plans to initiate a Phase 2 trial for SP001 in Sjögren’s disease in China by early 2027.
- SP001 is a third-generation, humanized, Fc-silent anti-CD40L antibody.
Price Impact
More from SPRO